Hepatocellular CarcinomaProHype-ICGNCT05800561
Prognostic Role of HVPG and ICG-R15 in the Short- and Medium-term Results of the Surgery of HCC on Cirrhosis
An observational study of Hepatocellular Carcinoma, run by Federico II University at 1 site in Italy.
Trial summary
AIMS To evaluate the accuracy of HVPG (direct method), ICG-R15 and LSM/SSM (non-invasive methods) in predicting the risk of PHLF and hepatic decompensation; to evaluate the correlation between hepatic functional reserve (ICG-R15) and degree of portal hypertension (HVPG) and LSM/SSM in Child Pugh 0, A and B cirrhotic… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hepatocellular Carcinoma
- What is being tested?
- Hepatic venous-portal gradient (HVPG) measurement
- How many people
- 208 participants
- Where
- 1 siteItaly
- Study dates
- 1 Jan 2022to 31 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cirrhotic patients with HCC undergoing liver resection
Who may be able to join
- All adult patients with liver cirrhosis with indication for surgical resection for hepatocellular carcinoma are considered eligible. Patients will be selected for surgery based on standard criteria of participating centers and on Child-Pugh score 0, A or B
Who cannot join
- Patients undergoing emergency surgery; inability to understand informed consent.
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Federico II University Hospital
Naples, 80131
Roberto R Troisi, MD, PhD
Gianluca Cassese, MD
About this study
Official title: Prognostic Role of the Pressure Gradients of Portal Hypertension and of the Hepatic Functional Reserve Estimated by Indocyanine Green Test in the Short- and Medium-term Results of the Surgery of Hepatocellular Carcinomas on Cirrhosis
AIMS To evaluate the accuracy of HVPG (direct method), ICG-R15 and LSM/SSM (non-invasive methods) in predicting the risk of PHLF and hepatic decompensation; to evaluate the correlation between hepatic functional reserve (ICG-R15) and degree of portal hypertension (HVPG) and LSM/SSM in Child Pugh 0, A and B cirrhotic patients; to evaluate the real weight of HVPG in a multivariate analysis.
METHODS: Multicentric observational prospective study. INCLUSION CRITERIA: All patients with liver cirrhosis with indication for surgical resection for hepatocellular carcinoma are considered eligible. Patients will be selected for surgery based on standard criteria of participating centers and on Child-Pugh score 0, A or B.
Read more
EXCLUSION CRITERIA: Patients undergoing emergency surgery; inability to understand informed consent.
Primary endpoint: Comparison of the predictive accuracy (evaluated as Area Under The Curve of the ROC curve, see statistics) of HVPG, ICG and Liver and Spleen Stiffness of Post-operative Hepatic Failure (PHLF, according to ISGLS).
Secondary endpoints: - Predictive accuracy of HVPG, ICG-R15, LSM and SSM on postoperative morbidity at 90 days according to the classification of Clavien-Dindo and to the Comprehensive Complication Index (CCI), and on cirrhosis decompensation at 3 months after surgery.
Read the detailed description
BACKGROUND: Most of current guidelines for the treatment of Hepatocellular Carcinoma (HCC) are based on the Barcelona Clinic Liver Cancer (BCLC) staging system1, where Portal Hypertension (PHT) alone contraindicates surgery2. However, the evolution of surgical techniques and patient management has led many centers to overcome the limits proposed by BCLC3, highlighting the need for new criteria and to consider additional factors tailored on each patient4,5. Almost all papers analyzing the prognostic role of PHT in patients undergoing liver surgery are based on retrospective data and on an indirect assessment of the presence of PHT, that have been shown to have less prognostic role7. Among the indirect methods of PHT assessment, hepatic elastography using FibroScan® has been recently consolidated. LSM is known to be related to postoperative outcomes, but its impact on the subset of PHT patients, as well as a comparison with SSM or HPVG, has never been investigated. Given the splenic congestion secondary to PHT, new diagnostic algorithms for CSPH take into account the spleen stiffness (SSM, with 46kPa cut-off)8. SSM has also been shown to be related to post-operative outcomes9. In the pre-operative evaluations on the extent of resection a key role is played by the hepatic functional reserves estimated with the blood retention at 15 'of Indocyanine Green (ICG-R15). It has been proposed a relationship between ICG blood levels and hepatic venous pressure gradient (HVPG), even if only in Child A patients6. ICG-r15' has never been compared to LSM and SSM for postoperative outcomes.
AIMS To evaluate the accuracy of HVPG (direct method), ICG-R15 and LSM/SSM (non-invasive methods) in predicting the risk of PHLF and hepatic decompensation; to evaluate the correlation between hepatic functional reserve (ICG-R15) and degree of portal hypertension (HVPG) and LSM/SSM in Child Pugh 0, A and B cirrhotic patients; to evaluate the real weight of HVPG in a multivariate analysis that takes into account patient demographics, CHILD, MELD, tumor characteristics, extent of surgery, blood loss, invasiveness of the approach, LSM, SSM.
METHODS: Multicentric prospective study. INCLUSION CRITERIA: All patients with liver cirrhosis with indication for surgical resection for hepatocellular carcinoma are considered eligible. Patients will be selected for surgery based on standard criteria of participating centers and on Child-Pugh score 0, A or B. EXCLUSION CRITERIA: Patients undergoing emergency surgery; inability to understand informed consent. Primary endpoint: Comparison of the predictive accuracy (evaluated as Area Under The Curve of the ROC curve, see statistics) of HVPG, ICG and Liver and Spleen Stiffness of Post-operative Hepatic Failure (PHLF, according to ISGLS). Secondary endpoints: - Predictive accuracy of HVPG, ICG-R15, LSM and SSM on postoperative morbidity at 90 days according to the classification of Clavien-Dindo and to the Comprehensive Complication Index (CCI), and on cirrhosis decompensation at 3 months after surgery. Statistic analysis Comparisons between groups will be performed using student's T test or Wilcoxon's rank test for continuous data, depending on the distribution of the variable. Categorical data will be compared by using Pearson's Chi Square test. The presence of a linear correlation between variables will be verified by linear regression. The accuracy of a continuous variable in predicting a categorical outcome will be evaluated using the Receiver Operating Characteristic (ROC) curves. The value of the area under the curve (AUC), will be used as an index of predictive accuracy. The comparison between the AUC of different variables will be performed by the method described by Hanley et al. A univariate and multivariate analysis will also be performed including risk factors for surgery in cirrhotic patients, including also LSM and SSM.
- Conditions
- Hepatocellular Carcinoma
- Being tested
- Hepatic venous-portal gradient (HVPG) measurement
- Medical subject headings
- Carcinoma, Hepatocellular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hepatic venous-portal gradient (HVPG) measurementDiagnostic test
Also called ICG-retention test
preoperative evaluation of Hepatic venous-portal gradient (HVPG) and ICG-retention test
What is being measured
The primary outcome is the main question the study is designed to answer.
predictive accuracy of HVPG and ICG-r15 on PHLF
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Apr 2023
- Study start1 Jan 2022
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Jan 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hepatocellular CarcinomaStudies of the same condition, open and under way.
- More trials run by Federico II UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 208 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Federico II University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Roberto Ivan Troisi, Federico II University
- Investigators
- Roberto I Troisi, Md, PhD, Principal investigator, Department of Clinical Medicine and Surgery, Federico II University of Naples
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05800561
- Sponsor's protocol ID
- 368/20
- Acronym
- ProHype-ICG
- Status last verified
- Mar 2023
- First submitted
- 24 Mar 2023
- Last updated
- 5 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prognostic Role of the Pressure Gradients of Portal Hypertension and of the Hepatic Functional Reserve Estimated by Indocyanine Green Test in the Short- and Medium-term Results of the Surgery of Hepatocellular Carcinomas on Cirrhosis
- ClinicalTrials.gov ID
- NCT05800561
- Acronym / sponsor ID
- ProHype-ICG / 368/20
- Conditions
- Hepatocellular Carcinoma
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 208 participants (estimated)
- Lead sponsor
- Federico II UniversityUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Jan 2024 (estimated)
- First posted
- 5 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
AIMS To evaluate the accuracy of HVPG (direct method), ICG-R15 and LSM/SSM (non-invasive methods) in predicting the risk of PHLF and hepatic decompensation; to evaluate the correlation between hepatic functional reserve (ICG-R15) and degree of portal hypertension (HVPG) and LSM/SSM in Child Pugh 0, A and B cirrhotic patients; to evaluate the real weight of HVPG in a multivariate analysis.
METHODS: Multicentric observational prospective study. INCLUSION CRITERIA: All patients with liver cirrhosis with indication for surgical resection for hepatocellular carcinoma are considered eligible. Patients will be selected for surgery based on standard criteria of participating centers and on Child-Pugh score 0, A or B.
EXCLUSION CRITERIA: Patients undergoing emergency surgery; inability to understand informed consent.
Primary endpoint: Comparison of the predictive accuracy (evaluated as Area Under The Curve of the ROC curve, see statistics) of HVPG, ICG and Liver and Spleen Stiffness of Post-operative Hepatic Failure (PHLF, according to ISGLS).
Secondary endpoints: - Predictive accuracy of HVPG, ICG-R15, LSM and SSM on postoperative morbidity at 90 days according to the classification of Clavien-Dindo and to the Comprehensive Complication Index (CCI), and on cirrhosis decompensation at 3 months after surgery.
Detailed description
BACKGROUND: Most of current guidelines for the treatment of Hepatocellular Carcinoma (HCC) are based on the Barcelona Clinic Liver Cancer (BCLC) staging system1, where Portal Hypertension (PHT) alone contraindicates surgery2. However, the evolution of surgical techniques and patient management has led many centers to overcome the limits proposed by BCLC3, highlighting the need for new criteria and to consider additional factors tailored on each patient4,5. Almost all papers analyzing the prognostic role of PHT in patients undergoing liver surgery are based on retrospective data and on an indirect assessment of the presence of PHT, that have been shown to have less prognostic role7. Among the indirect methods of PHT assessment, hepatic elastography using FibroScan® has been recently consolidated. LSM is known to be related to postoperative outcomes, but its impact on the subset of PHT patients, as well as a comparison with SSM or HPVG, has never been investigated. Given the splenic congestion secondary to PHT, new diagnostic algorithms for CSPH take into account the spleen stiffness (SSM, with 46kPa cut-off)8. SSM has also been shown to be related to post-operative outcomes9. In the pre-operative evaluations on the extent of resection a key role is played by the hepatic functional reserves estimated with the blood retention at 15 'of Indocyanine Green (ICG-R15). It has been proposed a relationship between ICG blood levels and hepatic venous pressure gradient (HVPG), even if only in Child A patients6. ICG-r15' has never been compared to LSM and SSM for postoperative outcomes.
AIMS To evaluate the accuracy of HVPG (direct method), ICG-R15 and LSM/SSM (non-invasive methods) in predicting the risk of PHLF and hepatic decompensation; to evaluate the correlation between hepatic functional reserve (ICG-R15) and degree of portal hypertension (HVPG) and LSM/SSM in Child Pugh 0, A and B cirrhotic patients; to evaluate the real weight of HVPG in a multivariate analysis that takes into account patient demographics, CHILD, MELD, tumor characteristics, extent of surgery, blood loss, invasiveness of the approach, LSM, SSM.
METHODS: Multicentric prospective study. INCLUSION CRITERIA: All patients with liver cirrhosis with indication for surgical resection for hepatocellular carcinoma are considered eligible. Patients will be selected for surgery based on standard criteria of participating centers and on Child-Pugh score 0, A or B. EXCLUSION CRITERIA: Patients undergoing emergency surgery; inability to understand informed consent. Primary endpoint: Comparison of the predictive accuracy (evaluated as Area Under The Curve of the ROC curve, see statistics) of HVPG, ICG and Liver and Spleen Stiffness of Post-operative Hepatic Failure (PHLF, according to ISGLS). Secondary endpoints: - Predictive accuracy of HVPG, ICG-R15, LSM and SSM on postoperative morbidity at 90 days according to the classification of Clavien-Dindo and to the Comprehensive Complication Index (CCI), and on cirrhosis decompensation at 3 months after surgery. Statistic analysis Comparisons between groups will be performed using student's T test or Wilcoxon's rank test for continuous data, depending on the distribution of the variable. Categorical data will be compared by using Pearson's Chi Square test. The presence of a linear correlation between variables will be verified by linear regression. The accuracy of a continuous variable in predicting a categorical outcome will be evaluated using the Receiver Operating Characteristic (ROC) curves. The value of the area under the curve (AUC), will be used as an index of predictive accuracy. The comparison between the AUC of different variables will be performed by the method described by Hanley et al. A univariate and multivariate analysis will also be performed including risk factors for surgery in cirrhotic patients, including also LSM and SSM.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cirrhotic patients with HCC undergoing liver resection
Key inclusion criteria (1 listed)
- All adult patients with liver cirrhosis with indication for surgical resection for hepatocellular carcinoma are considered eligible. Patients will be selected for surgery based on standard criteria of participating centers and on Child-Pugh score 0, A or B
Key exclusion criteria (1 listed)
- Patients undergoing emergency surgery; inability to understand informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hepatic venous-portal gradient (HVPG) measurementAlso: ICG-retention testpreoperative evaluation of Hepatic venous-portal gradient (HVPG) and ICG-retention test | Diagnostic test | – |
Primary outcome
predictive accuracy of HVPG and ICG-r15 on PHLF
Time frame: 90 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Apr 2023.
- Individual participant dataSharing planned: Undecided
Related trials for Hepatocellular Carcinoma
RecruitingObservational study
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
Liver Neoplasms, Primary Liver Cancer
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingObservational study
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Lung Cancer, Hepatocellular Carcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Roberto I Troisi, Md, PhD principal investigator
Department of Clinical Medicine and Surgery, Federico II University of Naples
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatocellular Carcinoma, run by Federico II University at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Roberto I Troisi, Md, PhD (+390817462776, roberto.troisi@unina.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
predictive accuracy of HVPG and ICG-r15 on PHLF (time frame: 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Apr 2023.